Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-219-0 | CAS number: 15174-47-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.
Cross-reference
- Reason / purpose:
- read-across: supporting information
Reference
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.
- Reason / purpose:
- read-across source
- Qualifier:
- no guideline available
- Version / remarks:
- A 14-Day Study of Hexyl Cinnamic Aldehyde by Oral (Gavage) in Rats
- Principles of method if other than guideline:
- A range finding 14-day oral gavage study on HCA
- GLP compliance:
- yes (incl. certificate)
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Analytical verification of doses or concentrations:
- yes
- Frequency of treatment:
- once daily via gavage for 14 consecutive days
- Remarks:
- Doses / Concentrations:
0,100,250,500,1000mg/kg/day
Basis:
actual ingested - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Based on effects (not adverse) observed at the 250 mg/Kg/day dose
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 250 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Based on effects (not adverse) observed at the 500 mg/Kg/day dose
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on mortality and adverse effects observed at the 1000 mg/Kg/day dose
- Critical effects observed:
- not specified
- Conclusions:
- In this 14-day repeat-dose study, hexyl cinnamic aldehyde was administered orally by gavage to 5 rats/sex/dosage at 0 (Vehicle), 100, 250, 500 and 1000 mg/kg/day. Several rats died or were euthanized after two or three days of treatment at 1000 mg/kg/day, and dosage administration in this dosage group was subsequently discontinued. Clinical signs attributed to hexyl cinnamic aldehyde were primarily observed at 1000 mg/kg/day, and a few observations of excess salivation occurred in males and females at 500 mg/kg/day. At 1000 mg/kg/day, net losses in body weight were observed in both sexes during the first three days of dosage administration, with transient reductions in body weight gain occurring at 250 and/or 500 mg/kg/day during the same period. Corresponding reductions in feed consumption occurred in male and female rats given 1000 mg/kg/day ofhexyl cinnamic aldehyde during the first three days ofthe study. Gross pathological observation revealed irritation of the gastric mucosa in male and female rats that died or were euthanized early in the 1000 mg/kg/day dosage group. Microscopic examination revealed test substance-related changes in the kidneys and in the stomach at 1000 mg/kg/day. No gross pathological or microscopic changes attributable to treatment with hexyl cinnamic aldehyde were observed at dosages up to 500 mg/kg/day.
In the conditions of this test hexyl cinnamic aldehyde has an NOAEL 14d oral of 500 mg/kg/bw/day
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Version / remarks:
- A 14-Day Study of Hexyl Cinnamic Aldehyde by Oral (Gavage) in Rats
- Principles of method if other than guideline:
- A range finding 14-day oral gavage study on HCA
- GLP compliance:
- yes (incl. certificate)
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Test material form:
- liquid
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Analytical verification of doses or concentrations:
- yes
- Frequency of treatment:
- once daily via gavage for 14 consecutive days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0,100,250,500,1000mg/kg/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Based on effects (not adverse) observed at the 250 mg/Kg/day dose
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 250 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Based on effects (not adverse) observed at the 500 mg/Kg/day dose
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on mortality and adverse effects observed at the 1000 mg/Kg/day dose
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In this 14-day repeat-dose study, hexyl cinnamic aldehyde was administered orally by gavage to 5 rats/sex/dosage at 0 (Vehicle), 100, 250, 500 and 1000 mg/kg/day. Several rats died or were euthanized after two or three days of treatment at 1000 mg/kg/day, and dosage administration in this dosage group was subsequently discontinued. Clinical signs attributed to hexyl cinnamic aldehyde were primarily observed at 1000 mg/kg/day, and a few observations of excess salivation occurred in males and females at 500 mg/kg/day. At 1000 mg/kg/day, net losses in body weight were observed in both sexes during the first three days of dosage administration, with transient reductions in body weight gain occurring at 250 and/or 500 mg/kg/day during the same period. Corresponding reductions in feed consumption occurred in male and female rats given 1000 mg/kg/day ofhexyl cinnamic aldehyde during the first three days ofthe study. Gross pathological observation revealed irritation of the gastric mucosa in male and female rats that died or were euthanized early in the 1000 mg/kg/day dosage group. Microscopic examination revealed test substance-related changes in the kidneys and in the stomach at 1000 mg/kg/day. No gross pathological or microscopic changes attributable to treatment with hexyl cinnamic aldehyde were observed at dosages up to 500 mg/kg/day.
In the conditions of this test hexyl cinnamic aldehyde has an NOAEL 14d oral of 500 mg/kg/bw/day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1